| (Values in U.S. Thousands) | Mar, 2023 | Dec, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 |
| Sales | 0 | 0 | 0 | 0 | 1,370 |
| Sales Growth | unch | unch | unch | -100.00% | +26.85% |
| Net Income | -11,090 | -9,180 | -12,330 | -4,090 | -11,210 |
| Net Income Growth | -20.81% | +25.55% | -201.47% | +63.51% | +5.64% |
Reunion Neuroscience Inc (REUN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Reunion Neuroscience Inc. is involved in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes. The Company's lead asset consist RE-104. Reunion Neuroscience Inc., formerly known as Field Trip Health Ltd., is based in TORONTO.
Fiscal Year End Date: 03/31